Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative and Postoperative Erlotinib with Gemcitabine in Resectable Pancreatic Cancer
NCT00841035Phase 2Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2009
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Alabama at Birmingham. Started Feb 2009; status: terminated.
02
Drugs
erlotinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00841035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00841035.